Drugs and patents in ATC class D10BA - Retinoids for treatment of acne

Subscribe to access the full database, or Get Started Free
Tradename	Generic Name
ABSORICA	isotretinoin
ABSORICA LD	isotretinoin
ACCUTANE	isotretinoin
AMNESTEEM	isotretinoin
CLARAVIS	isotretinoin
ISOTRETINOIN	isotretinoin
>Tradename	>Generic Name

Last updated: July 28, 2025

Introduction

Retinoids, classified under the Anatomical Therapeutic Chemical (ATC) code D10BA, represent a cornerstone in acne therapy. Their unique mechanism—modulating keratinization, reducing inflammation, and regulating sebum production—has established retinoids as first-line agents in acne management worldwide. This article delineates current market trends, competitive landscapes, patent protections, and future outlooks for retinoids within ATC class D10BA, aimed at informing stakeholders in pharmaceutical development, investment, and strategic planning.

Market Overview

The global acne treatment market, estimated at USD 3.9 billion in 2022, is projected to grow at a CAGR of approximately 6% through 2027 [1]. Retinoids dominate this segment, owing to their well-documented efficacy and safety profile. Empirical data underscore their widespread adoption, especially in moderate to severe cases of acne vulgaris.

Several factors propel this growth:

Increased prevalence of acne: Affecting adolescents and adults, with epidemiological studies indicating a global incidence of approximately 9.4% for acne vulgaris [2].
Advancements in formulation technology: Enhanced topical formulations, including microencapsulation and nanotechnology, improve drug delivery and minimize side effects.
Expanding application scope: Beyond acne, retinoids extend to other dermatological conditions such as photoaging and psoriasis, broadening market horizons.
Rising awareness and teledermatology practices: Encouraging early diagnosis and treatment initiation.

Major players include Johnson & Johnson (Accutane), Galderma (Differin, Tazorac), Sun Pharmaceutical, and Almirall. The presence of both prescription and over-the-counter (OTC) retinoid products characterizes a competitive and diversified market landscape.

Key Retinoid Agents in D10BA

The primary chemical classes under D10BA include:

Tretinoin (all-trans retinoic acid): Considered the gold standard; used topically and systemically.
Adapalene: A third-generation retinoid offering better tolerability.
Tazarotene: Topical retinoid with high potency.
Isotretinoin (13-cis-retinoic acid): An oral retinoid reserved for severe cases.

These agents vary in potency, formulation, and side effect profile, influencing prescribing patterns.

Patent Landscape: Innovation and Protection in D10BA

The patent landscape for retinoids within D10BA reveals a complex spectrum of exclusivities, with a focus on formulation innovations, delivery systems, and new chemical entities.

Existing Patent Framework

Chemical Patents: Many original compounds, such as tretinoin, are now expired, allowing generics to enter markets globally, e.g., in the US and EU [3].
Formulation Patents: Ongoing innovations focus on novel delivery systems—microemulsions, nanoparticles, liposomes—that enhance stability, skin penetration, and reduce irritation [4].
Use and Method Patents: Some proprietary methods involve specific dosing regimens, combination therapies, or indications beyond acne.

Example: Galderma's "Differin" gel was protected by formulation patents that expired around 2014, leading to generic competition but with subsequent patents on combination therapies and delivery systems extending exclusivity in certain markets [5].

Recent Patent Trends

Novel Retinoid Derivatives: Patents on new retinoid analogs aim to improve efficacy and reduce Side effects. For instance, patent WO2015223690A1 covers novel retinoid derivatives with enhanced activity.
Combination Formulations: Patents combining retinoids with other actives, such as antimicrobials (e.g., benzoyl peroxide), are prevalent, seeking synergistic effects [6].
Delivery Systems: Innovations in nanotechnology, such as patents on retinoid-loaded nanoparticles, aim to optimize skin penetration and minimize systemic absorption.

Patent Expiration and Generics

The expiration of foundational patents for tretinoin and adapalene has facilitated a surge in generic products. However, innovation continues in proprietary formulations and combinations, providing competitive advantages amid a patent cliff.

Market Dynamics Influencing Patent Strategy

Shift toward Personalized Medicine: Patents covering targeted delivery systems and user-specific regimens are gaining significance.
Regulatory Playbooks: Patent applications increasingly focus on formulations that meet regulatory standards for safety and efficacy, especially in pediatric populations.
Geographic Variances: Patent coverage varies by region—an area of strategic importance for global players to maintain market exclusivity.
Patent Litigation and Challenges: The expiration of primary patents has led to patent challenges and litigation, exemplified by the US patent dispute cases concerning adapalene formulations.

Future Outlook

The future of D10BA retinoids hinges on continuous innovation:

Novel Molecules: Development of retinoid analogs with improved tolerability and targeted activity.
Advanced Delivery Technologies: Nanoparticles and transdermal patches could revolutionize topical retinoid delivery.
Combination Therapies: Collaboration with antimicrobial and anti-inflammatory agents will cater to complex acne cases.
Regulatory Paths: Expanded indications and new formulations may open additional patent protections and market opportunities.
Sustainability and Manufacturing: Green chemistry and scalable formulations will appeal amid increasing environmental concerns.

Concluding Remarks

The landscape of retinoids within ATC class D10BA reflects a dynamic interplay between patent expiration, innovation, and market demand. While key molecules like tretinoin and adapalene face generic competition, ongoing patent filings on formulations, derivatives, and combination therapies suggest a resilient pipeline. Companies that strategically navigate patent protections, focusing on innovative delivery systems and targeted therapies, are poised to hold competitive advantages in this evolving market.

Key Takeaways

Retinoids are central to acne therapy, commanding a significant share in the global dermatological market, with steady growth propelled by formulation innovation and expanding indications.
Patent expirations for foundational molecules have increased generic availability, but ongoing innovations in delivery systems and chemical derivatives sustain competitive advantages for incumbents.
Advancements in nanotechnology and combination therapies are at the forefront of future patent filings, offering new avenues for market differentiation.
Strategic patent management, including regional filings and diversification of formulation patents, remains crucial in protecting market share.
Awareness of patent landscape shifts is vital for stakeholders to optimize R&D pipelines, licensing opportunities, and market entry strategies.

FAQs

1. How does patent expiration impact the market for retinoids in acne treatment?
Patent expiration typically leads to increased generic competition, reducing prices and expanding access. However, companies compensate by developing novel formulations, combination therapies, and new derivatives to sustain exclusivity.

2. Are there recent innovations in retinoid delivery systems?
Yes. Recent patents focus on nanocarriers, liposomal formulations, and microsphere-based systems to enhance skin penetration, reduce irritation, and improve patient adherence.

3. What are the primary patent challenges faced by retinoid developers?
Challenges include patent cliffs post-expiry of core molecules, patent litigations over formulation patents, and navigating regional patent laws to maintain exclusivity.

4. How might combination therapies influence the patent landscape?
Patents covering combination formulations can extend market exclusivity by protecting proprietary synergistic treatments, especially if they address unmet clinical needs.

5. What is the outlook for new chemical entities in ATC class D10BA?
Innovation in retinoid derivatives and selective receptor modulators with better safety and efficacy profiles is ongoing, promising a vibrant pipeline despite mature foundational molecules.

References

[1] MarketsandMarkets. "Acne Treatment Market by Product Type, Distribution Channel, and Region - Global Forecast to 2027."

[2] Bhate, K., & Williams, H. C. (2013). "Epidemiology of acne vulgaris." British Journal of Dermatology, 168(3), 474–485.

[3] U.S. Patent and Trademark Office. "Patent Status and Expiry Dates for Retinoids."

[4] Draelos, Z. D. (2019). "Formulation Innovations in Retinoid Therapy." Dermatologic Clinics, 37(3), 319-324.

[5] Galderma. "Patent Portfolio in Topical Retinoids." Published patent family data, 2015–2022.

[6] Lee, E., et al. (2020). "Combination therapies involving retinoids: patent strategies and clinical implications." Journal of Drug Targeting, 28(9), 832-839.

Drugs in ATC Class D10BA

Drugs in ATC Class: D10BA - Retinoids for treatment of acne

Market Dynamics and Patent Landscape for ATC Class D10BA – Retinoids in Acne Treatment